X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
azd6140 (133) 133
clopidogrel (106) 106
humans (84) 84
index medicus (82) 82
ticagrelor (82) 82
adenosine - analogs & derivatives (75) 75
safety (54) 54
acute coronary syndromes (48) 48
pharmacology & pharmacy (45) 45
male (44) 44
aspirin (40) 40
cardiac & cardiovascular systems (39) 39
female (37) 37
middle aged (36) 36
prasugrel (36) 36
p2y receptor antagonist (35) 35
inhibition (34) 34
ticlopidine - analogs & derivatives (32) 32
adenosine - adverse effects (31) 31
receptor antagonist (31) 31
adenosine - administration & dosage (30) 30
antagonist (30) 30
pharmacokinetics (30) 30
p2y (29) 29
platelet aggregation inhibitors - adverse effects (29) 29
adenosine (26) 26
adenosine - therapeutic use (26) 26
antiplatelet therapy (26) 26
treatment outcome (26) 26
adenosine - pharmacokinetics (25) 25
acute coronary syndrome (23) 23
adenosine - pharmacology (23) 23
aged (23) 23
pharmacodynamics (23) 23
platelet aggregation inhibitors - therapeutic use (22) 22
acute coronary syndrome - drug therapy (21) 21
cangrelor (21) 21
platelet aggregation inhibitors - administration & dosage (21) 21
platelets (20) 20
abridged index medicus (19) 19
adult (19) 19
drug therapy (19) 19
platelet aggregation - drug effects (18) 18
purinergic p2y receptor antagonists - adverse effects (18) 18
dose-response relationship, drug (17) 17
double-blind method (17) 17
hematology (17) 17
outcomes (17) 17
percutaneous coronary intervention (17) 17
platelet-aggregation (17) 17
purinergic p2 receptor antagonists (17) 17
purinergic p2y receptor antagonists - pharmacokinetics (17) 17
tolerability (17) 17
coronary heart disease (16) 16
heart attacks (16) 16
platelet inhibition (16) 16
purinergic p2y receptor antagonists - administration & dosage (16) 16
thrombosis (16) 16
ticlopidine - administration & dosage (16) 16
animals (15) 15
peripheral vascular disease (15) 15
platelet aggregation inhibitors - pharmacokinetics (15) 15
purinergic p2y receptor antagonists - therapeutic use (15) 15
administration, oral (14) 14
platelet aggregation inhibitors - pharmacology (14) 14
receptors, purinergic p2y12 (14) 14
ticlopidine - therapeutic use (14) 14
aggregation (13) 13
blood platelets (13) 13
dosage and administration (13) 13
dyspnea (13) 13
trial (13) 13
blood platelets - drug effects (12) 12
myocardial-infarction (12) 12
therapy (12) 12
ticlopidine - adverse effects (12) 12
cardiac patients (11) 11
cardiovascular disease (11) 11
care and treatment (11) 11
coronary artery disease (11) 11
double-blind (11) 11
platelet aggregation (11) 11
purinergic p2y receptor antagonists - pharmacology (11) 11
research (11) 11
analysis (10) 10
follow-up studies (10) 10
time factors (10) 10
aspirin - therapeutic use (9) 9
medicine, general & internal (9) 9
pharmacology (9) 9
young adult (9) 9
adp (8) 8
cardiovascular (8) 8
drug therapy, combination (8) 8
p2y antagonist (8) 8
p2y receptor (8) 8
pharmacology/toxicology (8) 8
plato (8) 8
acute coronary syndrome - physiopathology (7) 7
bleeding (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Coronary Artery Disease, ISSN 0954-6928, 08/2019, Volume 30, Issue 5, pp. 317 - 322
BACKGROUNDTicagrelor significantly reduced the incidence of death, myocardial infarction, and stent thrombosis in patients with ST-segment elevation myocardial... 
clopidogrel | AZD6140 | CARDIAC & CARDIOVASCULAR SYSTEMS | SAFETY | primary percutaneous coronary intervention | REPERFUSION | ticagrelor | RECEPTOR ANTAGONIST | TRIAL | RESPONSES | ANGIOPLASTY | PLATELET INHIBITION | myocardial perfusion | OUTCOMES | Heart | Usage | Surgery | Patient outcomes | Perfusion (Physiology) | Drug therapy | Ticagrelor | Health aspects | Heart attack
Journal Article
BMC cardiovascular disorders, ISSN 1471-2261, 2019, Volume 19, Issue 1, pp. 51 - 11
ObjectivesTo evaluate the impact of a rapid change in preferred treatment from clopidogrel to ticagrelor on the risk of ischemic stroke following acute... 
AZD6140 | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | ANTAGONIST | EVENTS | ACUTE CORONARY SYNDROMES | PLATO | Ischemic stroke | TRENDS | Antiplatelet therapy | CLOPIDOGREL | INHIBITION | PREDICTORS | Secondary prevention | Acute myocardial infarction | Myocardial Infarction - epidemiology | Humans | Middle Aged | Stroke - diagnosis | Clopidogrel - administration & dosage | Incidence | Ticagrelor - adverse effects | Time Factors | Platelet Aggregation Inhibitors - administration & dosage | Ticagrelor - administration & dosage | Registries | Stroke - epidemiology | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Myocardial Infarction - diagnosis | Stroke - prevention & control | Risk Assessment | Comorbidity | Risk Factors | Treatment Outcome | Brain Ischemia - prevention & control | Sweden - epidemiology | Myocardial Infarction - drug therapy | Brain Ischemia - diagnosis | Aged | Clopidogrel - adverse effects | Transluminal angioplasty | Stroke (Disease) | Usage | Care and treatment | Ticagrelor | Myocardial infarction | Cerebral infarction | Stroke | Intensive care | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | Family medical history | Congestive heart failure | Patients | Glomerular filtration rate | Prevention | Fibrillation | Ischemia | Atherosclerosis | Diuretics | Clopidogrel | Diabetes | Acute coronary syndromes | Statins
Journal Article
Platelets, ISSN 0953-7104, 02/2019, Volume 30, Issue 2, pp. 199 - 205
Platelets are traditionally considered to be essential components of primary hemostasis. Recent investigations have revealed that platelets can be activated in... 
apoptosis | platelet | ticagrelor | Acute kidney injury | sepsis | AZD6140 | P2Y INHIBITORS | ANTAGONIST | SAFETY | NEUTROPHIL RECRUITMENT | CELL BIOLOGY | CLOPIDOGREL | INFLAMMATION | P-SELECTIN | HEMATOLOGY
Journal Article
Journal Article
International journal of cardiology, ISSN 0167-5273, 2019, Volume 287, pp. 19 - 26
The aim of this study is to investigate the impact of ticagrelor as compared to clopidogrel based dual antiplatelet therapy (DAPT) during post-discharge... 
Clopidogrel | Left ventricular thrombus | Anterior ST elevation myocardial infarction | Ticagrelor | Dual antiplatelet therapy | AZD6140 | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | RECEPTOR ANTAGONIST | ATRIAL-FIBRILLATION | PERCUTANEOUS CORONARY INTERVENTION | WARFARIN | PREDICTORS | PLATELET INHIBITION | OUTCOMES | Purinergic P2Y Receptor Antagonists - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Heart Diseases - prevention & control | Male | Clopidogrel - administration & dosage | ST Elevation Myocardial Infarction - diagnosis | Aspirin - administration & dosage | Incidence | Dose-Response Relationship, Drug | Heart Ventricles | Heart Diseases - epidemiology | Platelet Aggregation Inhibitors - administration & dosage | Ticagrelor - administration & dosage | Female | Retrospective Studies | Anterior Wall Myocardial Infarction - drug therapy | Thrombosis - prevention & control | Anterior Wall Myocardial Infarction - complications | Dual Anti-Platelet Therapy - methods | ST Elevation Myocardial Infarction - complications | Echocardiography | ST Elevation Myocardial Infarction - drug therapy | Thrombosis - epidemiology | Treatment Outcome | Coronary Angiography | Heart Diseases - etiology | Turkey - epidemiology | Thrombosis - etiology | Aged | Anterior Wall Myocardial Infarction - diagnosis
Journal Article
Pharmaceutical Chemistry Journal, ISSN 0091-150X, 1/2019, Volume 52, Issue 10, pp. 813 - 819
An effective and convenient process for the preparation of ticagrelor (1), an antiplatelet drug, has been developed. The synthesis of 1 is a four-step... 
synthesis | pilot-scale test | Pharmacy | process optimization | ticagrelor | response surface methodology | one-pot reaction | Pharmacology/Toxicology | Organic Chemistry | AZD6140 | CHEMISTRY, MEDICINAL | ANTAGONIST | P2Y | PHARMACOLOGY & PHARMACY
Journal Article
Therapeutic advances in drug safety, ISSN 2042-0994, 2018, Volume 9, Issue 10, pp. 577 - 584
Dyspnoea, a common and multifactorial symptom in patients with acute coronary syndrome, has been associated with lower quality of life and hospital... 
adverse effects | ticagrelor | antiplatelet | dyspnoea | acute coronary syndromes | cardiology | AZD6140 | ANTAGONIST | SAFETY | PLATO | ACUTE CORONARY SYNDROME | ASPIRIN | CLOPIDOGREL | THERAPY | PHARMACOLOGY & PHARMACY | OUTCOMES | Acute coronary syndromes | Patients | Dyspnea
Journal Article
European journal of clinical pharmacology, ISSN 1432-1041, 2018, Volume 74, Issue 6, pp. 745 - 754
Ticagrelor, the first reversible P2Y12 receptor antagonist, exhibits faster onset and offset of antiplatelet effects and more consistent platelet inhibition... 
Biomedicine | Maximal platelet inhibition | Simulation | CYP3A53 | CYP3A41G | AR-C124910XX | Pharmacology/Toxicology | Ticagrelor | Population pharmacokinetics and pharmacodynamics | Turnover model | AZD6140 | ANTAGONIST | SAFETY | GENOTYPE | OPEN-LABEL | CLOPIDOGREL | INHIBITION | STANDARD-DOSE TICAGRELOR | TOLERABILITY | PHARMACOLOGY & PHARMACY | P2Y RECEPTOR | Purinergic P2Y Receptor Antagonists - pharmacology | Adenosine - pharmacokinetics | Purinergic P2Y Receptor Antagonists - administration & dosage | Humans | Asian Continental Ancestry Group - genetics | Purinergic P2Y Receptor Antagonists - pharmacokinetics | Male | Purinergic P2Y Receptor Antagonists - blood | Adenosine - pharmacology | Adenosine - administration & dosage | Healthy Volunteers | Dose-Response Relationship, Drug | Young Adult | Adenosine - blood | Cytochrome P-450 CYP3A - genetics | Models, Biological | Adenosine - analogs & derivatives | Adult | Platelet Aggregation - drug effects | Polymorphism, Single Nucleotide | Blood Platelets - drug effects | Single nucleotide polymorphisms | Coronary heart disease | Analysis | Cardiac patients | Cytochrome P-450 | Pharmacodynamics | Computer simulation | Coronary artery | Cardiovascular disease | Population studies | Pharmacology | Single-nucleotide polymorphism | Coronary artery disease | Optimization | Mens health | Blood platelets | Biotransformation | Clopidogrel | Inhibition | Pharmacokinetics | Platelets | Heart diseases | Asians
Journal Article
Journal of molecular structure, ISSN 0022-2860, 2018, Volume 1170, pp. 38 - 43
N1N2 bond in molecules containing 1, 2, 3-triazoles framework is weakened and readily cleaved when N1 is attached to a strong electron-withdrawing group.... 
Ticagrelor | Triazole | Isomerization | BENZOTRIAZOLES | AZD6140 | ANTAGONIST | CHEMISTRY, PHYSICAL | IDENTIFICATION | IMPURITIES | HPLC | Drugstores | Pyrimidines | Triazoles | Pharmacy | Analysis
Journal Article
by Liu, HL and Wei, YJ and Ding, P and Zhang, J and Li, TC and Wang, B and Wang, MS and Li, YT and Zhang, JJ and Ren, YH and Tang, Q and Luo, JP and Yang, SL and Ma, HY and Liu, Y and Han, W and Li, Y and Jin, ZG and Jin, LM
CANADIAN JOURNAL OF CARDIOLOGY, ISSN 0828-282X, 12/2017, Volume 33, Issue 12, pp. 1675 - 1682
Background: We hypothesized that a high ticagrelor loading dose (LD) may improve platelet inhibition in patients with non-ST-elevation acute coronary syndrome... 
DEFINITION | AZD6140 | CARDIAC & CARDIOVASCULAR SYSTEMS | CLOPIDOGREL | ANTAGONIST | SAFETY | GUIDELINES | CONSENSUS | TREATMENT PLATELET REACTIVITY | OUTCOMES
Journal Article
by Easton, J Donald and Aunes, Maria and Albers, Gregory W and Bokelund-Singh, Sara and Denison, Hans and Evans, Scott R and Held, Peter and Jahreskog, Marianne and Jonasson, Jenny and Minematsu, Kazuo and Wang, Yongjun and Wong, K.S Lawrence and Johnston, S Claiborne and Ameriso, Sebastiá F and Donnan, Geoffrey and Lemmens, Robin and Massaro, Ayrton and Titianova, Ekaterina and Hill, Michael D and Lavados, Pablo and Skoloudik, David and Norbert, Szegedi and Góngora, Angel Arauz and Pretell, Edwin and San Jose, Maria Cristina Z and Bajenaru, Ovidiu and Stakhovskaya, Ludmila and Kim, Jong-Sung and Wahlgren, Nils and Lee, Tsong Hai and Kasner, Scott and Laskowitz, Daniel and Nguyen, Huy Thang and Lepera, Sandra and Paulon, David and Ioli, Pablo and Zurru, Cristina and Bruera, Guadalupe and Jure, Lorena and Klein, Francisco and Povedano, Guillermo and Levi, Christopher and Phan, Thanh and Markus, Romesh and Sabet, Arman and Kleinig, Timothy and Krause, Martin and Jannes, Jim and Wijeratne, Tissa and Hemelsoet, Dimitri and Peeters, André and Vanacker, Peter and Laloux, Patrice and Van Landegem, William and Vanhooren, Geert and Desfontaines, Philippe and Oliveira, Fabio and Brondani, Rosane and Fabio, Soraia and Dracoulakis, Marianna and Bazan, Rodrigo and Pontes Neto, Octavio and Silva, Gisele and Kowacs, Pedro and Stamenova, Paraskeva and Daskalov, Marin and Staikov, Ivan and Maslarov, Dimitar and Lilovski, Hristo and Petkov, Plamen and Petrova, Neli and Mavrov, Radoslav and Markova, Veska and Petrova, Valeria and Kralev, Borislav and Sotirov, Nikolay and Lekova, Veska and Hristov, Dimcho and Ermenkova, Vera and Mitkova, Rumeliya and Ikonomov, Rosen and Georgiev, Ivan and Shuaib, Ashfaq and Hachinski, Vladimir and Boulanger, Jean-Martin and Mann, Sharan and Hassan, Ayman and Mackey, Ariane and Menon, Bijoy and Minuk, Jeffrey and Vieira, Lucia and Selchen, Daniel and Beaudry, Michel and Stotts, Grant and Castro, Angel and Rivas, Rodrigo and Sanchez, Pablo and Roldan, Andres and Grossmann, Ingrid and Figueroa, Christian and ... and SOCRATES Steering Comm and SOCRATES Steering Committee and Investigators and For the SOCRATES Steering Committee and Investigators
Circulation, ISSN 0009-7322, 09/2017, Volume 136, Issue 10, pp. 907 - 916
Journal Article
Journal of Heterocyclic Chemistry, ISSN 0022-152X, 01/2017, Volume 54, Issue 1, pp. 436 - 449
A series of novel 6‐alkylamino(alkoxyl)‐2‐propylthio‐8‐azapurine nucleosides were synthesized by an improved route, and the human antiplatelet aggregation... 
CHEMISTRY, ORGANIC | AZD6140 | THERAPY | INHIBITORS | ANALOGS | RECEPTOR ANTAGONIST | Nucleosides | Analysis
Journal Article
Korean Circulation Journal, ISSN 1738-5520, 09/2017, Volume 47, Issue 5, pp. 689 - 691
Journal Article
Internal medicine journal, ISSN 1444-0903, 2017, Volume 47, Issue 11, pp. 1298 - 1305
Journal Article